The Relationship between Health Insurance and Pharmaceutical Innovation: An Empirical Study Based on Meta-Analysis.
effect size
health insurance
meta-analysis
pharmaceutical innovation
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
07 Nov 2023
07 Nov 2023
Historique:
received:
09
09
2023
revised:
02
11
2023
accepted:
03
11
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
The growing research interest in the relationship between health insurance and pharmaceutical innovation is driven by their significant impact on healthcare optimization and pharmaceutical development. The existing literature, however, lacks consensus on this relationship and provides no evidence of the magnitude of a correlation. In this context, this study employs meta-analysis to explore the extent to which health insurance affects pharmaceutical innovation. It analyzes 202 observations from 14 independent research samples, using the regression coefficient of health insurance on pharmaceutical innovation as the effect size. The results reveal that there is a strong positive correlation between health insurance and pharmaceutical innovation (r = 0.367, 95% CI = [0.294, 0.436]). Public health insurance exhibits a stronger promoting effect on pharmaceutical innovation than commercial health insurance. The relationship between health insurance and pharmaceutical innovation is moderated by the country of sample origin, data range, journal type, journal impact factor, type of health insurance, and research perspective. Our research findings further elucidate the relationship mechanism between health insurance and pharmaceutical innovation, providing a valuable reference for future explorations in pharmaceutical fields.
Identifiants
pubmed: 37998407
pii: healthcare11222916
doi: 10.3390/healthcare11222916
pmc: PMC10671039
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Social Science Fund of China
ID : 16 ZDA236
Références
Ann Intern Med. 2008 Feb 5;148(3):169-77
pubmed: 18180465
Am Econ Rev. ;96(2):103-7
pubmed: 29131561
Health Aff (Millwood). 2016 Sep 1;35(9):1725-33
pubmed: 27534776
Health Econ. 2005 Jan;14(1):1-16
pubmed: 15386673
Lancet. 2017 Dec 9;390(10112):2584-2594
pubmed: 29231837
Int Health. 2019 Sep 2;11(5):403-416
pubmed: 30912800
Galen Med J. 2019 Oct 14;8:e1411
pubmed: 34466508
J Ment Health Policy Econ. 2012 Sep;15(3):105-18
pubmed: 23001279
J Public Econ. 2013 Jan;97:327-336
pubmed: 23869113
Milbank Q. 2020 Jun;98(2):297-371
pubmed: 32191359
Am Econ Rev. 2010 Mar;100(1):590-607
pubmed: 29508975
Health Policy. 2019 Jan;123(1):71-79
pubmed: 30429060
Eur J Health Econ. 2019 Aug;20(6):841-856
pubmed: 30923986
Ther Innov Regul Sci. 2019 Nov;53(6):746-751
pubmed: 31771361
Health Aff (Millwood). 2001 Sep-Oct;20(5):216-20
pubmed: 11558706
JAMA. 2016 Jul 19;316(3):271-2
pubmed: 27149663
Healthcare (Basel). 2022 Sep 09;10(9):
pubmed: 36141345
J Health Econ. 2013 Dec;32(6):1356-67
pubmed: 24308884
J Health Econ. 2003 Mar;22(2):151-85
pubmed: 12606142
J Health Econ. 2008 Jul;27(4):1060-1077
pubmed: 18395277
Issue Brief (Commonw Fund). 2010 Jun;89:1-12
pubmed: 20614652
Nat Rev Drug Discov. 2012 Mar 30;11(4):253-4
pubmed: 22460109
Nature. 2018 Mar 7;555(7695):175-182
pubmed: 29517004
Lancet. 2022 Jun 4;399(10341):2129-2154
pubmed: 35617980
Health Policy. 2019 Jan;123(1):62-70
pubmed: 30340906
Stat Med. 1998 Apr 30;17(8):841-56
pubmed: 9595615
Food Res Int. 2023 Aug;170:112999
pubmed: 37316069
J Health Econ. 2019 Jan;63:64-80
pubmed: 30458314
Health Econ. 2017 Apr;26(4):431-449
pubmed: 26856894
Eur J Health Econ. 2013 Apr;14(2):323-44
pubmed: 22290504